TABLE 2.
Characterization of LUAD tumors with an identifiable TP53 c.1010G>A pathogenic variant.
| Identifier | Gender | Age at LUAD diagnosis (years) | Histological subtype | Somatic EGFR mutation | TP53 c.1010G>A zygosity | WT*/TP53 c.1010G>A allele frequency (coverage) | Percentage of tumor cells in the sample |
| 1 | Male | 57 | NA† | p.(Leu858Arg) | Heterozygous | 0.52/0.48 (2,400x) | 40% |
| 2 | Male | 65 | Lepidic | p.(Ser768_Asp770dup) | Heterozygous | 0.37/0.63 (2,259x) | 30% |
| 3 | Female | 55 | NA | p.(Leu858Arg) | Heterozygous | 0.24/0.76 (4,000x) | 60% |
| 4 | Female | 60 | Lepidic | None | Heterozygous | 0.42/0.58 (1,802x) | 40% |
| 5 | Female | 74 | NA | p.(Leu858Arg) | Heterozygous | 0.42/0.58 (1,835x) | 70% |
| 6 | Female | 54 | Lepidic | Inconclusive§ | Heterozygous | NP‡ | 5% |
| 7 | Female | 62 | Acinar | Inconclusive | Heterozygous | NP | 40% |
* WT, wild-type allele; † NA, not available; ‡ NP, not performed; § Inconclusive status due to technical limitations, such as availability of a low concentration of DNA extracted from the tumor tissue, and/or poor quality/purity of the tumor DNA, leading to inadequate results (low coverage) in the NGS analysis.